Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 730357 dose-ranging trial in psoriatic arthritis
ACTRN12620001092987Phase 2Not yet recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2022
- Modality
- Small Molecules
- Countries
- 18
01
Overview
Phase 2, randomised, double-blind trial of bevurogant in psoriatic arthritis (PsA) (4 arms), sponsored by Boehringer Ingelheim. Primary endpoint: ACR20 response. Planned start Apr 2022; status: not yet recruiting.
02
Drugs
bevurogant
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on ACTRN12620001092987.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12620001092987.